Skip to content
Screener

Total Revenue at other companies

Schrodinger logo
SchrodingerSDGR
$58.89M+7.5%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$7.67M-60.1%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$4.05M-76.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.56M-8.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$13.37M+38.9%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$13.82M+38.1%

Other financials

Income statement

See full
Operating income-$34.2M-8.8%
Net income-$33.2M-8.6%
EPS (diluted)-$0.21+12.5%

Balance sheet

See full
Cash & equivalents$108.9M+97.0%
Total debt$3.7M-32.2%
Total equity$246.1M+42.0%
Total assets$268.9M+28.1%

Cash flow

See full
Operating cash flow-$27.6M-63.4%
CapEx$1.0K-99.6%
Free cash flow-$27.6M-61.2%

Valuation

See full
Market cap$1.84B+248%
Enterprise value$1.74B+242%
P/S1,181.8×+993×

Profitability

See full
Operating margin-8,084.5%-17,708pp
Net margin-7,756.4%-17,069pp
FCF margin-6,981%-10,936pp

Returns & leverage

See full
Return on equity-57.7%+0.3pp
Debt / equity0×0.0×
Current ratio10.6×+6.2×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Absci Corporation’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001672688-26-000136
(In thousands, except for share and per share data)For the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Partner program revenue$318$593$533$1,772
Operating expenses
Research and development22,61620,45841,89136,822
Selling, general and administrative9,1648,52818,22218,000
Depreciation and amortization2,6963,0005,4246,072
Total operating expenses34,47631,98665,53760,894
Operating loss(34,158)(31,393)(65,004)(59,122)
Other income (expense)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's total revenue?
Absci Corporation (ABSI) reported total revenue of $318K in Q2 2026.
How has Absci Corporation's total revenue changed year-over-year?
Absci Corporation's total revenue decreased by 46.4% year-over-year, from $593K to $318K.
What is the long-term trend for Absci Corporation's total revenue?
Over 4 years (2021 to 2025), Absci Corporation's total revenue has grown at a -12.5% compound annual growth rate (CAGR), from $4.78M to $2.8M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Absci Corporation's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude